Overview Dividends

(RCKT) Rocket Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US77313F1066

Gene, Therapy, Cardiomyopathy, Anemia, Immunodeficiency

Biotechnology
Market Cap in USD: 380m
IPO / Inception: 2015-02-18
Return 12m vs S&P 500: -75.1%

EPS (Earnings per Share)

EPS (Earnings per Share) of RCKT over the last years for every Quarter: "2020-12": -1.08, "2021-03": -0.65, "2021-06": -0.55, "2021-09": -0.79, "2021-12": -0.69, "2022-03": -0.67, "2022-06": -0.83, "2022-09": -0.87, "2022-12": -0.92, "2023-03": -0.73, "2023-06": -0.82, "2023-09": -0.75, "2023-12": -0.64, "2024-03": -0.66, "2024-06": -0.74, "2024-09": -0.71, "2024-12": -0.62, "2025-03": -0.56, "2025-06": -0.62, "2025-09": -0.45,
EPS CAGR: 16.97%
EPS Trend: 67.7%
Last SUE: 0.61
Qual. Beats: 0

Revenue

Revenue of RCKT over the last years for every Quarter: 2020-12: 0, 2021-03: 0, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 10.312, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 9.186, 2025-03: 0, 2025-06: 0, 2025-09: 0,
Rev. CAGR: 0.00%
Rev. Trend: 20.2%
Last SUE: -0.17
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 65.9%
Value at Risk 5%th 91.6%
Relative Tail Risk -15.49%
Reward TTM
Sharpe Ratio -0.50
Alpha -90.28
CAGR/Max DD -0.48
Character TTM
Hurst Exponent 0.429
Beta 1.248
Beta Downside 1.945
Drawdowns 3y
Max DD 92.71%
Mean DD 43.29%
Median DD 32.92%

Description: RCKT Rocket Pharmaceuticals October 28, 2025

Rocket Pharmaceuticals (NASDAQ:RCKT) is a late-stage biotech focused on AAV-based gene therapies for rare, high-mortality diseases in the U.S., with a pipeline that spans preclinical to Phase 2 trials.

Its AAV program includes RP-A501 for Danon disease (Phase 2), RP-A601 targeting Plakophilin-2 arrhythmogenic cardiomyopathy (Phase 1), and a preclinical BAG3-dilated cardiomyopathy candidate; the lentiviral (LV) platform advances RP-L201 (Leukocyte Adhesion Deficiency-I), RP-L102 (Fanconi Anemia) and RP-L301 (Pyruvate Kinase Deficiency).

Key financial metrics (as of Q2 2024) show a market capitalization of roughly $120 million, cash and equivalents of $45 million, and a monthly cash burn of about $6 million, giving the company an estimated runway of 7–8 months without additional financing.

The gene-therapy sector is driven by a projected CAGR of ~15 % through 2030, buoyed by FDA’s accelerated pathways for rare diseases and increasing payer willingness to reimburse curative therapies, which could amplify the commercial upside of Rocket’s orphan-drug pipeline.

For a deeper quantitative assessment, you may find ValueRay’s analyst dashboard useful.

Piotroski VR‑10 (Strict, 0-10) 1.0

Net Income (-240.9m TTM) > 0 and > 6% of Revenue (6% = 551.2k TTM)
FCFTA -0.55 (>2.0%) and ΔFCFTA -3.70pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 2139 % (prev 1957 %; Δ 182.5pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.55 (>3.0%) and CFO -202.2m > Net Income -240.9m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 7.30 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (111.6m) change vs 12m ago 18.49% (target <= -2.0% for YES)
Gross Margin 39.82% (prev -17.71%; Δ 57.53pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 2.41% (prev 2.62%; Δ -0.21pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -126.4 (EBITDA TTM -227.9m / Interest Expense TTM 1.89m) >= 6 (WARN >= 3)

Altman Z'' -40.10

(A) 0.53 = (Total Current Assets 227.7m - Total Current Liabilities 31.2m) / Total Assets 368.0m
(B) -3.80 = Retained Earnings (Balance) -1.40b / Total Assets 368.0m
warn (B) unusual magnitude: -3.80 — check mapping/units
(C) -0.63 = EBIT TTM -239.0m / Avg Total Assets 380.9m
(D) -25.71 = Book Value of Equity -1.40b / Total Liabilities 54.4m
Total Rating: -40.10 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 40.86

1. Piotroski 1.0pt
2. FCF Yield data missing
3. FCF Margin data missing
4. Debt/Equity 0.08
5. Debt/Ebitda 0.22
6. ROIC - WACC (= -72.02)%
7. RoE -62.44%
8. Rev. Trend 20.18%
9. EPS Trend 67.74%

What is the price of RCKT shares?

As of December 28, 2025, the stock is trading at USD 3.48 with a total of 934,739 shares traded.
Over the past week, the price has changed by +7.74%, over one month by +5.78%, over three months by +6.75% and over the past year by -71.05%.

Is RCKT a buy, sell or hold?

Rocket Pharmaceuticals has received a consensus analysts rating of 4.61. Therefore, it is recommended to buy RCKT.
  • Strong Buy: 12
  • Buy: 5
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the RCKT price?

Issuer Target Up/Down from current
Wallstreet Target Price 8 128.4%
Analysts Target Price 8 128.4%
ValueRay Target Price 2.3 -33%

RCKT Fundamental Data Overview December 27, 2025

Market Cap USD = 379.9m (379.9m USD * 1.0 USD.USD)
P/B = 1.211
Beta = 0.655
Revenue TTM = 9.19m USD
EBIT TTM = -239.0m USD
EBITDA TTM = -227.9m USD
Long Term Debt = 25.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.91m USD (from shortTermDebt, last quarter)
Debt = 25.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -50.9m USD (from netDebt column, last quarter)
Enterprise Value = 182.1m USD (379.9m + Debt 25.0m - CCE 222.8m)
Interest Coverage Ratio = -126.4 (Ebit TTM -239.0m / Interest Expense TTM 1.89m)
FCF Yield = -111.3% (FCF TTM -202.8m / Enterprise Value 182.1m)
FCF Margin = -2208 % (FCF TTM -202.8m / Revenue TTM 9.19m)
Net Margin = -2623 % (Net Income TTM -240.9m / Revenue TTM 9.19m)
Gross Margin = 39.82% ((Revenue TTM 9.19m - Cost of Revenue TTM 5.53m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 0.49 (Enterprise Value 182.1m / Total Assets 368.0m)
Interest Expense / Debt = 1.89% (Interest Expense 473.0k / Debt 25.0m)
Taxrate = 0.00% (-1.0 / -258.7m)
NOPAT = -239.0m (EBIT -239.0m * (1 - 0.00%)) [loss with tax shield]
Current Ratio = 7.30 (Total Current Assets 227.7m / Total Current Liabilities 31.2m)
Debt / Equity = 0.08 (Debt 25.0m / totalStockholderEquity, last quarter 313.7m)
Debt / EBITDA = 0.22 (negative EBITDA) (Net Debt -50.9m / EBITDA -227.9m)
Debt / FCF = 0.25 (negative FCF - burning cash) (Net Debt -50.9m / FCF TTM -202.8m)
Total Stockholder Equity = 385.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -65.46% (Net Income -240.9m / Total Assets 368.0m)
RoE = -62.44% (Net Income TTM -240.9m / Total Stockholder Equity 385.8m)
RoCE = -58.18% (EBIT -239.0m / Capital Employed (Equity 385.8m + L.T.Debt 25.0m))
RoIC = -61.95% (negative operating profit) (NOPAT -239.0m / Invested Capital 385.8m)
WACC = 10.07% (E(379.9m)/V(404.9m) * Re(10.61%) + D(25.0m)/V(404.9m) * Rd(1.89%) * (1-Tc(0.00)))
Discount Rate = 10.61% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 15.24%
Fair Price DCF = unknown (Cash Flow -202.8m)
EPS Correlation: 67.74 | EPS CAGR: 16.97% | SUE: 0.61 | # QB: 0
Revenue Correlation: 20.18 | Revenue CAGR: 0.0% | SUE: -0.17 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.44 | Chg30d=+0.002 | Revisions Net=+1 | Analysts=7
EPS next Year (2026-12-31): EPS=-1.29 | Chg30d=+0.000 | Revisions Net=-3 | Growth EPS=+35.9% | Growth Revenue=+0.0%

Additional Sources for RCKT Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle